EL Raises FY27 Outlook, But DeepValue Maintains WAIT

What happened

Estée Lauder used its Capital Markets Day to raise FY27 guidance and outline a path to 18.5% operating margin by fiscal 2030, citing improving sales, share gains in China, and increased use of AI and regionalization. This positive narrative follows Q1 FY2026 results that showed 4% revenue growth and a return to positive operating income, though the company still carries a stretched balance sheet with net debt/EBITDA of 34x and negative interest coverage. The stock has already rallied ~29% over the past year to $94.71, trading at extreme multiples such as EV/EBITDA of 214x and a DCF-implied value of only $10.76, suggesting the market is pricing in a rapid and successful turnaround. Management's claims about China share stabilization are noteworthy but require validation through sustained mid-single-digit revenue growth and structurally lower SG&A in coming quarters, especially given historical share loss in that market. While the long-term margin target of 18.5% by 2030 is ambitious, it is still far below pre-2022 levels, and without clear evidence of FCF normalization and deleveraging, the risk/reward remains unattractive for new capital.

Implication

Investors should treat the FY27 outlook and 2030 margin target as management's aspirational roadmap, not a confirmed trajectory; execution on PRGP and China recovery must be demonstrated over multiple quarters before upgrading the thesis. The stock's recent rally means any disappointment in China or travel retail could lead to significant downside given the lack of margin of safety at current prices. Monitoring points from the DeepValue report remain critical: consecutive quarters of mid-single-digit revenue growth, gross margin at 73-75%, and net debt/EBITDA trending down are prerequisites for a potential BUY. Conversely, if leverage metrics worsen or China share losses continue, the stance should shift toward POTENTIAL SELL. Patience is warranted; better entry points may emerge if the market re-rates the stock to reflect ongoing financial risk.

Thesis delta

The DeepValue stance of WAIT remains unchanged. The new 2030 margin and FY27 guidance are directionally consistent with the existing watch items on PRGP execution and Asia recovery, but they are long-term promises rather than near-term proof. Without tangible improvement in FCF and leverage metrics, there is no basis to upgrade the thesis at this time.